We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Invitrogen Corporation Announces Strategic Collaboration With BMG Labtech Inc.
News

Invitrogen Corporation Announces Strategic Collaboration With BMG Labtech Inc.

Invitrogen Corporation Announces Strategic Collaboration With BMG Labtech Inc.
News

Invitrogen Corporation Announces Strategic Collaboration With BMG Labtech Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen Corporation Announces Strategic Collaboration With BMG Labtech Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics, and BMG LABTECH Inc. are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with BMG LABTECH’s microplate detection instruments.

Invitrogen’s drug discovery products will be tested on certain BMG LABTECH microplate readers, and select BMG LABTECH instruments, such as the PHERAstar and OMEGA series, will be certified for use with specific Invitrogen technology platforms. Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen™ TR-FRET for protein kinases, PolarScreen™ FP technology for nuclear receptors, GeneBLAzer® reporter-gene technology for G protein-coupled receptors and Adapta™, a new TR-FRET assay system for lipid kinases. This collaboration will allow BMG LABTECH and Invitrogen to develop and promote joint applications for the drug discovery market.

“Through this partnership, researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation and visa versa,” said John Printen, director of Invitrogen’s Cell Signaling business segment. “This is critical for reaching customers across pharmaceutical research, biotech, academics and government where those scientists are seeking a higher throughput solution for their discovery workflows.”

“BMG LABTECH has a strong installed customer base in both the pharmaceutical sector and the academic research market. Our customers in both market segments demand high performance instrumentation and assay systems.” says Dr. Ronald Earp, President of BMG LABTECH Inc. “This partnership will insure that their BMG LABTECH microplate readers will provide optimal performance on Invitrogen assay technologies and allow us to proactively develop instrumentation for future platforms.”

Advertisement